Free tools Windows power users keep installed
One-click scans. No signup required.
iTechGuides is reader-supported. When you buy through links on our site, we may earn an affiliate commission. As an Amazon Associate I earn from qualifying purchases. Learn more
FDA clearance for AI-based medical software depends on the product’s intended medical use, risk and predicate—not on the fact that it uses artificial intelligence. A typical Class II product with a legally marketed predicate follows the 510(k) pathway and receives clearance. A novel low- or moderate-risk product may need a De Novo request and receive a classification grant; a high-risk Class III product needs a PMA and receives approval. Before filing, define the claim, establish a quality system, generate representative clinical and technical evidence, address cybersecurity, and decide whether future model changes need an authorized Predetermined Change Control Plan (PCCP).
This U.S.-focused guide reflects FDA requirements and guidance available in November 2026. FDA says, “The FDA does not regulate AI as such; it regulates medical devices, including AI-enabled medical devices.”
What does FDA clearance mean for AI-based medical software?
“Clearance” is the outcome of a 510(k) premarket notification. It means FDA found the device substantially equivalent (SE) to a legally marketed predicate with the same intended use and either the same technological characteristics or differences that do not raise different questions of safety and effectiveness. It is not the same as FDA approval, and it is not a certification that an algorithm is universally accurate.
The Tool Desk
Outbyte Driver Updater FREEFix the driver behind crashes, sound loss and screen glitchesFind Drivers →Outbyte PC Repair FREEClear out junk files and repair common Windows errorsFree Scan →FDA’s own 510(k) description says: “A 510(k) is a premarket submission made to FDA to demonstrate that the device to be marketed is as safe and effective, that is, substantially equivalent, to a legally marketed device (section 513(i)(1)(A) FD&C Act).” FDA also states, “Until the submitter receives an order declaring a device SE, the submitter may not proceed to market the device.”
Popular on Amazon
- 【90 Degree Full Function USB C Adapter】Supports the latest USB4 standard for up to 40Gbps of bandwidth, 8K video support, and up to 240W Fast charging; Support USB PD 3.1 Extended Power Range (EPR) including 140W, 180W and 240W. Your productivity is easily doubled. *Warm Tip: For the best fit, please make sure the USB-C port is fully exposed; thick or bulky cases may affect compatibility.
- 【Reliable Quality】Made from high-quality, scratch-resistant aluminum alloy, delicate metal frame. get excellent wear resistance and heat dissipation. Non-Slip Design for easier insertion and removal.
- 【Small and portable】Ultra thin size, ultra compact design, a petite physique that matches the minimalist design of your modern laptops. Coming with a slim figure that won't block the port next to the one it's plugged into.
- 【Compatibility】Widely work with most usb c, thunderbolt 4/3 devices. Compatibilit for ROG Ally, Steam Deck, Switch, MacBook Pro, Quest 3 VR headset, Surface Book 2, iPhone 18/17/16/15, Samsung Galaxy S23/S22/S21, Note 20/10, Google Pixel, ChromeBook, etc.
- 【Excellence Customer Support】If you experience any issues or cable failure, simply reach out to our dedicated customer service team. We provide a prompt response within 18 hours, providing you with the necessary technical support to resolve any concerns.
As of September 2026, FDA reported over 1,600 AI-enabled medical devices authorized for U.S. marketing — U.S. FDA, 2026. A 5 September 2026 tabulation of FDA’s public list counted 1,614 entries, of which 96.2% carried a 510(k) number, 2.5% were De Novo and 1.3% were PMA — IntuitionLabs, 2026. FDA cautions that the public list “is not a comprehensive resource of AI-enabled medical devices,” so these figures are snapshots, not a complete census.
Is my AI health app a medical device or clinical decision support?
Start with the intended use and the product’s claims. Under section 201(h)(1) of the Federal Food, Drug, and Cosmetic Act, software is a device when it is intended to diagnose, cure, mitigate, treat or prevent disease, or to affect the structure or function of the body, unless a software function is excluded by section 520(o). A symptom checker marketed for general education can have a different regulatory status from software that diagnoses a condition or directs treatment, even when the underlying model is identical.
Software as a Medical Device (SaMD) performs a medical purpose without being part of a hardware medical device. For example, a cloud or phone application that analyzes a retinal image is generally SaMD. Software in a Medical Device (SiMD) is integral to a hardware device, such as an algorithm embedded in a dedicated imaging camera. FDA increasingly uses AI-enabled device software function (AI-DSF) for a device software function that implements one or more AI or machine-learning models.
Section 520(o) excludes certain functions, including administrative support for a health-care facility; healthy-lifestyle functions unrelated to disease; electronic patient records; transferring, storing, converting or displaying certain data; and clinical decision support (CDS) that meets every statutory criterion. For the CDS exclusion, the software must:
- Not acquire, process or analyze a medical image, an in-vitro diagnostic signal or a physiological waveform.
- Display, analyze or print medical information about a patient or other medical information.
- Support or provide recommendations to a health-care professional rather than issue a single time-critical directive to a patient.
- Enable the professional to independently review the basis for the recommendation so the clinician does not rely primarily on the software.
Image and signal analysis, autonomous diagnosis, patient-facing treatment instructions and opaque alerts that prevent independent review generally remain devices. If the boundary is uncertain, document the analysis and ask FDA through a Q-Submission (Pre-Sub); FDA’s Digital Health Center of Excellence lists DigitalHealth@fda.hhs.gov as a contact.
Which FDA pathway should an AI SaMD use?
Choose the pathway from risk class and predicate status, not from the use of AI. The same model could be a 510(k) device for assistive triage but require De Novo or PMA for an autonomous, high-risk diagnostic claim.
| Pathway | When it fits | FDA outcome | Core evidence argument | Review-time reference |
|---|---|---|---|---|
| 510(k) | Class I/II device with a legally marketed predicate sharing the intended use | Clearance after substantial-equivalence determination | Same intended use and no new safety/effectiveness questions from technology differences | FDA says SE is usually determined within 90 days; Grayde reported a 2024 AI/ML median of about 151 days (secondary analysis) |
| De Novo | Novel low- or moderate-risk device with no suitable predicate | Classification grant creating a new Class I or II regulation and future predicate | General controls, or general plus special controls, provide reasonable assurance of safety and effectiveness | 150 FDA-day MDUFA goal; Grayde reported a 2024 AI/ML median of about 372 days (secondary analysis) |
| PMA | Class III or otherwise high-risk device | Approval | Valid scientific evidence demonstrates safety and effectiveness | Grayde cites a 285-calendar-day shared-outcome goal for original PMAs received in FY2025–FY2027 (secondary analysis) |
FDA describes De Novo this way: “The De Novo request provides a marketing pathway to classify novel medical devices for which general controls alone, or general and special controls, provide reasonable assurance of safety and effectiveness for the intended use, but for which there is no legally marketed predicate device.” For PMA, FDA says: “Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.”
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Also popular on Amazon
- 5-in-1 Connectivity: Equipped with a 4K HDMI port, a 5 Gbps USB-C data port, two 5 Gbps USB-A ports, and a USB C 100W PD-IN port. Note: The USB C 100W PD-IN port supports only charging and does not support data transfer devices such as headphones or speakers.
- Powerful Pass-Through Charging: Supports up to 85W pass-through charging so you can power up your laptop while you use the hub. Note: Pass-through charging requires a charger (not included). Note: To achieve full power for iPad, we recommend using a 45W wall charger.
- Transfer Files in Seconds: Move files to and from your laptop at speeds of up to 5 Gbps via the USB-C and USB-A data ports. Note: The USB C 5Gbps Data port does not support video output.
- HD Display: Connect to the HDMI port to stream or mirror content to an external monitor in resolutions of up to 4K@30Hz. Note: The USB-C ports do not support video output.
- What You Get: Anker 332 USB-C Hub (5-in-1), welcome guide, our worry-free 18-month warranty, and friendly customer service.
Most AI-enabled devices have been Class II and entered through 510(k). QLogix, reporting The Imaging Wire’s analysis through June 2026, found 1,230 of 1,614 listed devices (76%) in radiology, with 92 authorizations in the first quarter of 2026 and 89 in the second — QLogix, 2026. These are list analyses, not a guarantee that a new product belongs in 510(k).
How do I prepare an AI device for an FDA submission?
Use the following sequence before you lock validation data or promise a launch date.
1. Freeze the intended use and indications
Write the user, patient population, input, output, clinical setting, workflow and level of autonomy. State whether the software informs, manages or drives a clinical decision. Define exclusions, contraindications, required input quality and what happens when the model cannot provide a reliable result. Marketing language must match the intended-use statement; adding a new disease, modality, patient group or patient-facing claim can change the pathway.
2. Analyze device status under sections 201(h) and 520(o)
Create a written device/non-device rationale, including the four CDS criteria if you claim an exclusion. Preserve screenshots, labeling and promotional claims because FDA evaluates intended use from the totality of those materials. If the conclusion is borderline, put the question in a Pre-Sub rather than relying on an informal assumption.
Quick wins for a faster PC:
Repair Windows errors before they cause bigger problemsFix Now →Scan for outdated or missing drivers - takes under a minuteDriver Scan →3. Search for a predicate and product code
Search FDA’s 510(k), De Novo and PMA databases, classification database and list of AI-enabled medical devices. Compare intended use, user, inputs, outputs and workflow—not merely whether both products use a neural network. Select one primary predicate; a split-predicate strategy is not a reliable substitute for substantial equivalence. Radiology computer-aided triage and notification products, for example, may use product code QAS, but the code must match the actual device.
4. Select the pathway and obtain early FDA feedback
For a first-of-kind AI-DSF, uncertain classification, unusual clinical evidence or a proposed PCCP, submit a Q-Submission to the responsible review division and Digital Health Center of Excellence. Ask specific questions about device status, class, predicate, study design, software documentation, cybersecurity, labeling, performance thresholds and the boundaries of proposed model updates. A Pre-Sub gives feedback; it does not itself clear the device or authorize a PCCP.
5. Establish the quality system before validation
FDA’s Quality Management System Regulation (QMSR), aligning 21 CFR Part 820 with ISO 13485:2016, took effect on 2 February 2026. Put design controls, risk management, requirements traceability, verification and validation, supplier controls, complaint handling, CAPA and change control in place before the pivotal test set is locked. Class II and Class III devices, and selected Class I devices, are subject to design-control requirements.
Also popular on Amazon
- Sleek 7-in-1 USB-C Hub: Features an HDMI port, two USB-A 3.0 ports, and a USB-C data port, each providing 5Gbps transfer speeds. It also includes a USB-C PD input port for charging up to 100W and dual SD and TF card slots, all in a compact design.
- Flawless 4K@60Hz Video with HDMI: Delivers exceptional clarity and smoothness with its 4K@60Hz HDMI port, making it ideal for high-definition presentations and entertainment. (Note: Only the HDMI port supports video projection; the USB-C port is for data transfer only.)
- Double Up on Efficiency: The two USB-A 3.0 ports and a USB-C port support a fast 5Gbps data rate, significantly boosting your transfer speeds and improving productivity.
- Fast and Reliable 85W Charging: Offers high-capacity, speedy charging for laptops up to 85W, so you spend less time tethered to an outlet and more time being productive.
- What You Get: Anker USB-C Hub (7-in-1), welcome guide, 18-month warranty, and our friendly customer service.
6. Build a secure software lifecycle
Maintain software architecture, requirements, hazard analysis, version history, unit and integration testing, release records and unresolved-anomaly assessments. FDA commonly expects lifecycle evidence consistent with IEC 62304-style practices. For a cyber device, section 524B requires processes for reasonable cybersecurity assurance and a premarket plan to monitor, identify and address postmarket vulnerabilities in a reasonable time. Include threat modeling, an SBOM where appropriate, secure update and rollback procedures, authentication, access control and incident response.
Do these 3 things before closing this tab:
1Fix the driver behind crashes, sound loss and screen glitches2Clear out junk files and repair common Windows errors3Scan for outdated or missing drivers - takes under a minuteWhat clinical and technical evidence does FDA expect for AI/ML SaMD?
Evidence must show that the specific device, in its intended population and workflow, performs safely and effectively. The evidence burden rises with risk and autonomy; there is no universal “AI study” accepted for every claim.
The FDA, Health Canada and UK MHRA’s October 2021 Good Machine Learning Practice (GMLP) guiding principles identify 10 principles:
- Use multidisciplinary expertise throughout the total product life cycle.
- Apply good software engineering and security practices.
- Use participants and datasets representative of the intended population.
- Keep training datasets independent of test datasets.
- Base reference datasets on the best available methods.
- Tailor model design to available data and intended use.
- Evaluate the performance of the human-AI team.
- Test under clinically relevant conditions.
- Give users clear, essential information.
- Monitor deployed performance and manage retraining risks.
For each dataset, document provenance, collector, inclusion and exclusion criteria, population match, reference standard, annotator qualifications, adjudication, train/tune/test splits, independence, subgroup representation and edge cases. Sequester the test set so tuning or repeated inspection cannot leak information into the final performance estimate. Report sensitivity, specificity, predictive values or other prespecified metrics with confidence intervals and clinically justified thresholds, along with failures and indeterminate outputs.
The IMDRF clinical-evaluation framework asks for three linked showings: valid clinical association, analytical validation and clinical validation. A 510(k) often uses retrospective, multi-site testing and, where relevant, multi-reader multi-case (MRMC) studies to support substantial equivalence. De Novo submissions add evidence supporting the new classification and proposed special controls. PMAs generally require valid scientific evidence, often including prospective pivotal investigations and, when applicable, IDE studies.
Do not equate technical accuracy with patient benefit. IntuitionLabs reported that a JAMA Network Open study of 903 devices found a substantial share explicitly stated that no performance studies were conducted. The same report cited a PLOS Digital Health analysis of 1,357 devices in which only 3 (0.2%) evaluated patient-centered outcomes such as mortality or readmission. Those are independent-study findings reported by IntuitionLabs, not FDA statistics, and they do not mean every device lacks clinical value.
How do I include a Predetermined Change Control Plan (PCCP)?
A PCCP is the mechanism for keeping specified, validated model changes inside an authorization. Section 515C of the FD&C Act permits a change consistent with an FDA-authorized PCCP without a new 510(k), De Novo supplement or PMA supplement, provided the device remains safe and effective and, for a 510(k), remains substantially equivalent.
Also popular on Amazon
- Portable and powerful USB-C HUB: BENFEI USB Type-C HUB, with super-soft and knot-free silicone woven design cable, meets most mobile office needs. Compact, lightweight, stylish, and powerful portable USB C Hub equipped with 1 x HDMI port, 1 x 100W charging, and 3 x USB ports. 18-month warranty, 24-hour response, to ensure you feel at ease when using our product.
- Design centered on comfort and reliability: Thanks to BENFEI's end-to-end in-house cable production capability, in-house PCBA and assembly capability, using the industry's most advanced silicone woven design and process, 20cm cable in length, no knots, super-soft, the HUB is easy to use in all scenarios: laptop, tablet, stand etc. Super-soft, 25000+ life cycles, to meet your daily carrying and office needs.
- 100W Charging: Support up to 90W USB C pass-through charging via Type-C port to keep your laptop powered. 10W is reserved for other interface operations. No data and video function on the Type-C port.
- 4K HDMI Display: The HDMI port supports media display at resolutions up to 4K 30Hz, keeping every incredible moment detailed and ultra vivid. Please note that the C port of the Host device needs to support video output.
- Transfer Files in Seconds: Transfer files and from your laptop at speeds up to 10 Gbps with USB A 3.2 port. Extra 2 USB A 2.0 ports are perfectly for your keyboards and mouse.
FDA’s definition, quoted by the Congressional Research Service, is “the documentation describing what modifications will be made to a device and how the modifications will be assessed.” FDA’s final AI-specific PCCP guidance was issued on 18 August 2025 (originally 4 December 2024) and applies to AI-enabled devices reviewed through 510(k), De Novo and PMA. It is nonbinding guidance; FDA states, “This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public.”
The guidance recommends three components:
- Description of Modifications. Specify limited, verifiable changes and their rationale, such as improving a quantitative performance metric, adding compatible inputs within defined specifications or improving performance for a named subpopulation. State whether updates are automatic or manual, global or local, and how often they may occur. Keep them within the authorized intended use.
- Modification Protocol. Describe data-management, retraining, performance-evaluation and update procedures. Include deployment, user communication, labeling, cybersecurity validation, real-world monitoring and rollback. Map every listed modification to acceptance criteria and verification methods.
- Impact Assessment. Analyze benefits and risks, alone and in combination, including unintended bias and subgroup effects. Explain how verification and validation preserve safety and effectiveness.
FDA says, “FDA reviews the PCCP as part of a marketing submission for a device to ensure the continued safety and effectiveness of the device without necessitating additional marketing submissions for implementing each modification described in the PCCP.” After authorization, implement only listed changes exactly according to the protocol and record them under the QMS. A new predictive claim, new patient-facing use, new modality or deviation from the protocol generally requires a new regulatory assessment and often a new submission. Do not market an open-ended promise that “the model continuously learns.” Draft the PCCP before the pivotal submission, and use a Q-Sub to discuss its scope.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchPC Slower Than It Used to Be?
A free scan shows the junk files, broken settings and background clutter dragging Windows down - then fixes them in one click.Free scan · Windows 10 & 11Users should be told that the device contains ML and has an authorized PCCP. Update notices should summarize the change, supporting data and affected inputs and outputs. A new model or version may require a new UDI. FDA’s public summaries should contain a high-level PCCP description. Independent research reported low voluntary PCCP adoption among devices authorized from 2023 through 2025, so a PCCP should not be assumed to exist for every cleared AI device.
What must go into the 510(k), De Novo or PMA file?
Use FDA’s electronic submission templates and tailor the content to the pathway and risk. A 510(k) or De Novo eSTAR submission is sent through the CDRH Customer Collaboration Portal; eSTAR has been required for 510(k)s since 1 October 2023 and for De Novo requests since 1 October 2025, unless an exemption applies.
- Administrative and device information: applicant, manufacturing locations, ownership, device name, classification, product code, intended use, indications, labeling and predicate or proposed classification.
- Software documentation: architecture, requirements, hazard analysis, cybersecurity, verification and validation, unresolved anomalies, version control, interoperability and human-factors information. FDA may expect basic or enhanced documentation depending on risk.
- AI-specific evidence: model description, training and tuning process, data provenance, independent test data, reference standard, subgroup and edge-case results, input-quality controls, failure modes, limitations and human-AI workflow.
- Clinical evidence: analytical and clinical validation appropriate to the claim; MRMC or prospective studies where needed; statistical analysis plan, protocol deviations and adverse events.
- Change and postmarket controls: PCCP, monitoring for drift and bias, complaint and incident processes, cybersecurity vulnerability response and update or rollback procedures.
For De Novo, FDA’s eSTAR asks for the recommended class, why general or special controls provide reasonable assurance, proposed special controls, clinical and nonclinical data, software information and benefit-risk analysis. Technical screening should occur within 15 calendar days when the fee is paid; an incomplete request can be placed on hold and must be replaced within 180 days. For a file that passes screening, the review clock starts on the receipt date. An Additional Information letter starts a 180-calendar-day complete-response period with no extensions. A granted De Novo creates a new regulation and product code that can support later 510(k)s.
All three pathways have MDUFA user fees, with reductions available through FDA’s Small Business Determination program. Amounts change by fiscal year; check the FDA MDUFA fee page for the amount checked at filing. Do not budget from an invented “average AI clearance cost.”
How long does FDA 510(k) take for AI software?
FDA says the SE determination is usually made within 90 days based on the submitted information. That is an FDA review-time statement, not a guaranteed end-to-end launch date. Refuse-to-accept or technical deficiencies, Additional Information requests, sponsor response time, clinical-study work and manufacturing readiness can extend calendar time. Grayde’s secondary analysis reported a median of about 151 days for AI/ML-enabled devices authorized in 2024 in a 510(k) context, compared with about 372 days for De Novo devices.
Also popular on Amazon
- 【Read before You Buy】 Note: This adapter is USB 2.0 version and cannot transmit HDM, VGA, or other video signals. Nevertheless, they are fully capable of charging devices,duplicating files, and can be seamlessly integrated with USB-C earphones, wireless network adapters, and SD card adapters.
- 【Easy to Use and Safe】Thanks to modern manufacturing techniques, we've made these adapters sufficiently compact so that they can remain inserted in your device without noticeable protrusion or inconvenience. This means you don't have to constantly plug and unplug them, reducing the likelihood of wear and misalignment, and making them more convenient to carry around.
- 【Reliable Quality】Engineered for enhanced durability, durable aluminum alloy shell material,get excellent wear resistance and heat dissipation,the male USB C and female USB connectors & the male USB and female USB C connectors are designed to be plugged and unplugged up to 20000 times. Provides data transfer, device charging, memory space expansion, and additional computer peripherals.
- 【Think more for you】Do you need to connect a USB-C-enabled device to an odd device that only has USB-A ports? Then these USB-A male to USB-C female adapters are made for you.Simply insert the adapter into the USB-A port on the device, and you can instantly connect your USB-C device to the device that originally didn't have the correct connection port.
- 【Trusted xiwxi Quality and Service】As a responsible brand seller, you will receive xiwxi's 12-month Quality assurance and lifetime friendly customer service, you're not just buying a product,you're investing in peace of mind with all-round quality and exceptional customer service.
Plan for the work before submission: intended-use and pathway decisions, Q-Sub interaction, QMS implementation, data collection and curation, locked validation, labeling, eSTAR assembly, fee payment and post-submission responses. Do not ship or advertise the device as FDA cleared until the SE order arrives. A De Novo request has a 150-FDA-day MDUFA performance goal, while a PMA has a much heavier evidence and review burden; the 285-calendar-day PMA figure cited for FY2025–FY2027 is a shared-outcome goal, not a promise.
What are the most common reasons AI-device submissions fail?
- Marketing before authorization: wait for the SE order, De Novo grant or PMA approval.
- Calling a 510(k) product “FDA approved”: use “FDA cleared” for 510(k), “FDA granted” for De Novo and “FDA approved” for PMA.
- Using AI as the pathway rationale: classify from intended use, risk and predicate evidence.
- Overreaching beyond the predicate: an autonomous diagnostic claim cannot usually rely on evidence designed for assistive triage.
- Data leakage or poor representativeness: separate training, tuning and test data and report subgroup performance.
- Vague continuous-learning language: define bounded changes and a three-part PCCP or treat each update under ordinary modification rules.
- PCCP scope creep: a new clinical claim, modality or patient-facing use is generally outside the authorized plan.
- Skipping a Q-Sub: first-of-kind AI-DSFs benefit from written FDA feedback on classification, evidence and update boundaries.
- Ignoring QMSR or cybersecurity: build design controls, vulnerability monitoring and secure-update processes before filing.
- Treating FDA’s AI list as exhaustive: the agency expressly says the list is not comprehensive.
What should a first-time AI SaMD sponsor do next?
- Freeze the intended use, indications, users, inputs, outputs and clinician role.
- Document the 201(h)/520(o) device analysis and CDS rationale, if applicable.
- Search FDA classifications, databases, product codes, predicates and the AI-enabled-device list.
- Select 510(k), De Novo or PMA without forcing a weak predicate.
- Implement QMSR/ISO 13485-aligned design controls, software lifecycle controls, risk management and section 524B cybersecurity processes.
- Separate and lock representative training, tuning and test datasets; define reference standards and subgroup analyses.
- Design standalone and, where relevant, human-AI performance studies around the exact claim.
- Use a Q-Sub to resolve classification, evidence, labeling, cybersecurity and PCCP questions.
- Draft the PCCP before the marketing submission if postmarket model changes are expected.
- Complete eSTAR, pay the current MDUFA fee and submit through the CDRH Portal.
- Hold inventory until the appropriate authorization arrives, then implement only authorized changes and monitor real-world drift, bias and cybersecurity.
FDA’s pathway is demanding because the claim—not the buzzword—determines what may be marketed. A disciplined intended-use statement, a defensible predicate or classification rationale, representative evidence, a functioning QMS and a tightly bounded PCCP give an AI medical-software sponsor the clearest route to lawful U.S. commercialization.
Frequently Asked Questions
Can FDA clear a generative AI medical device?
FDA’s June 2026 Congressional Research Service summary said the agency did not appear to have authorized a generative-AI-enabled device for marketing at that time. FDA has discussed generative AI through advisory meetings and a discussion paper, but that discussion paper is not itself a policy change; do not assume a foundation-model product has a special exemption.
Recommended Free Tools
Does a De Novo grant let another company use my device as a predicate?
Yes. A granted De Novo creates a new classification and product code, and a later device of the same generic type may use that device as a 510(k) predicate. The later product still must demonstrate substantial equivalence and satisfy any special controls.
Can a PCCP authorize a new disease indication?
Usually not. A PCCP is intended for bounded modifications that stay within the authorized intended use; adding a new disease, clinical claim, modality or patient-facing use is generally outside scope and should be evaluated as a new submission.
Does FDA inspect my facility before a 510(k) clearance?
FDA does not typically inspect the facility before issuing a 510(k) decision. A manufacturer must nevertheless maintain the applicable quality system and be prepared for an inspection after clearance, including records for design controls, production, complaints, CAPA and PCCP changes.

